Streetbeat News

Price Targets

FPAY

HC Wainwright & Co. analyst Scott Buck maintains a 'Buy' rating on FlexShopper (NASDAQ:FPAY) but has lowered the price target from $3 to $2.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:28 am

BTBT

HC Wainwright & Co. analyst Kevin Dede has reiterated a 'Buy' rating on Bit Digital (NASDAQ:BTBT) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:27 am

DTIL

HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Precision BioSciences (NASDAQ:DTIL) but lowers the price target from $5 to $3.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:23 am

MDWD

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on MediWound (NASDAQ:MDWD) and maintained a $23 price target.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:22 am

RPTX

HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Repare Therapeutics (NASDAQ:RPTX) but lowers the price target from $26 to $25.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:20 am

FRLN

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:17 am

YTEN

HC Wainwright & Co. analyst Amit Dayal maintains a 'Buy' rating on Yield10 Bioscience (NASDAQ:YTEN) but has lowered the price target from $25 to $4.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:16 am

CRGE

HC Wainwright & Co. analyst Amit Dayal has reiterated a 'Buy' rating on Charge Enterprises (NASDAQ:CRGE) and maintained a price target of $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:15 am

KMDA

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Kamada (NASDAQ:KMDA) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

August 17, 2023 | 10:13 am

LLY

Jim Cramer advises investors to hold off on buying Eli Lilly (NASDAQ:LLY) stocks despite the recent price surge. He suggests waiting for a pullback before purchasing, citing the rapid ascent of the stock as a cause for caution. A new 12-month price target of $600 for Eli Lilly has been set, indicating a potential 14% increase from the current price of around $528. The revised price target is influenced by the company's recent earnings report and its position as a leading growth story in large-cap pharma.

Portfolio Pulse from Benzinga Neuro

August 17, 2023 | 10:11 am